Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 317

1.

Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.

Fullard ME, Xie SX, Marek K, Stern M, Jennings D, Siderowf A, Willis AW, Chen-Plotkin AS.

Mov Disord. 2017 Sep 14. doi: 10.1002/mds.27127. [Epub ahead of print]

PMID:
28906025
2.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ.

Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review.

PMID:
28887905
3.

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.

Eidson LN, Kannarkat GT, Barnum CJ, Chang J, Chung J, Caspell-Garcia C, Taylor P, Mollenhauer B, Schlossmacher MG, Ereshefsky L, Yen M, Kopil C, Frasier M, Marek K, Hertzberg VS, Tansey MG.

J Neuroinflammation. 2017 Aug 18;14(1):164. doi: 10.1186/s12974-017-0935-1.

4.

Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis.

Conrado DJ, Nicholas T, Tsai K, Macha S, Sinha V, Stone J, Corrigan B, Bani M, Muglia P, Watson IA, Kern VD, Sheveleva E, Marek K, Stephenson DT, Romero K; Critical Path for Parkinson's (CPP) Parkinson's Disease Modeling and Simulation Working Group.

Clin Transl Sci. 2017 Jul 27. doi: 10.1111/cts.12492. [Epub ahead of print]

PMID:
28749580
5.

Portable objective assessment of upper extremity motor function in Parkinson's disease.

Chahine LM, Uribe L, Hogarth P, McNames J, Siderowf A, Marek K, Jennings D.

Parkinsonism Relat Disord. 2017 Jul 19. pii: S1353-8020(17)30264-X. doi: 10.1016/j.parkreldis.2017.07.017. [Epub ahead of print]

PMID:
28747279
6.

A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease.

Hayete B, Wuest D, Laramie J, McDonagh P, Church B, Eberly S, Lang A, Marek K, Runge K, Shoulson I, Singleton A, Tanner C, Khalil I, Verma A, Ravina B.

PLoS One. 2017 Jun 12;12(6):e0178982. doi: 10.1371/journal.pone.0178982. eCollection 2017.

7.

Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K; PARS Investigators.

JAMA Neurol. 2017 Aug 1;74(8):933-940. doi: 10.1001/jamaneurol.2017.0985.

PMID:
28595287
8.
9.

Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease.

Amara AW, Chahine LM, Caspell-Garcia C, Long JD, Coffey C, Högl B, Videnovic A, Iranzo A, Mayer G, Foldvary-Schaefer N, Postuma R, Oertel W, Lasch S, Marek K, Simuni T; Parkinson’s Progression Markers Initiative.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):653-662. doi: 10.1136/jnnp-2016-315023. Epub 2017 May 29.

PMID:
28554959
10.

Contribution of PPARγ in modulation of acrolein-induced inflammatory signaling in gp91phox knock-out mice.

Yousefipour Z, Chug N, Marek K, Nesbary A, Mathew J, Ranganna K, Newaz MA.

Biochem Cell Biol. 2017 Aug;95(4):482-490. doi: 10.1139/bcb-2016-0198. Epub 2017 Apr 4.

PMID:
28376311
11.

The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.

Pont-Sunyer C, Tolosa E, Caspell-Garcia C, Coffey C, Alcalay RN, Chan P, Duda JE, Facheris M, Fernández-Santiago R, Marek K, Lomeña F, Marras C, Mondragon E, Saunders-Pullman R, Waro B; LRRK2 Cohort Consortium.

Mov Disord. 2017 May;32(5):726-738. doi: 10.1002/mds.26964. Epub 2017 Mar 28.

PMID:
28370517
12.

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials.

Fleisher AS, Joshi AD, Sundell KL, Chen YF, Kollack-Walker S, Lu M, Chen S, Devous MD Sr, Seibyl J, Marek K, Siemers ER, Mintun MA.

Alzheimers Dement. 2017 Mar 30. pii: S1552-5260(17)30094-8. doi: 10.1016/j.jalz.2017.02.009. [Epub ahead of print]

PMID:
28365320
13.

Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects.

Barret O, Alagille D, Sanabria S, Comley RA, Weimer RM, Borroni E, Mintun M, Seneca N, Papin C, Morley T, Marek K, Seibyl JP, Tamagnan GD, Jennings D.

J Nucl Med. 2017 Jul;58(7):1124-1131. doi: 10.2967/jnumed.116.182881. Epub 2016 Dec 1.

PMID:
27908967
14.

Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective.

Isaacson SH, Fisher S, Gupta F, Hermanowicz N, Kremens DE, Lew MF, Marek K, Pahwa R, Russell DS, Seibyl J.

Expert Rev Neurother. 2017 Mar;17(3):219-225. doi: 10.1080/14737175.2017.1256205. Epub 2016 Nov 23. Review.

PMID:
27813429
15.

Abolishing the 1-year rule: How much evidence will be enough?

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G.

Mov Disord. 2016 Nov;31(11):1623-1627. doi: 10.1002/mds.26796. Epub 2016 Sep 26. No abstract available.

PMID:
27666574
16.

Profiling Patient Characteristics Associated With the Intensity of Nurse Care Coordination.

Kim TY, Marek KD.

West J Nurs Res. 2016 Aug 26. pii: 0193945916661493. [Epub ahead of print]

PMID:
27565836
17.

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.

Simuni T, Long JD, Caspell-Garcia C, Coffey CS, Lasch S, Tanner CM, Jennings D, Kieburtz KD, Marek K; PPMI Investigators.

Ann Clin Transl Neurol. 2016 May 17;3(7):482-94. doi: 10.1002/acn3.317. eCollection 2016 Jul.

18.

The new definition and diagnostic criteria of Parkinson's disease.

Postuma RB, Berg D, Adler CH, Bloem BR, Chan P, Deuschl G, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Oertel W, Olanow CW, Poewe W, Stern M.

Lancet Neurol. 2016 May;15(6):546-8. doi: 10.1016/S1474-4422(16)00116-2. Epub 2016 Apr 11. No abstract available.

PMID:
27302120
19.

Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease.

Lim NS, Swanson CR, Cherng HR, Unger TL, Xie SX, Weintraub D, Marek K, Stern MB, Siderowf A; PARS Investigators; Alzheimer's Disease Neuroimaging Initiative, Trojanowski JQ, Chen-Plotkin AS.

Ann Clin Transl Neurol. 2016 Mar 29;3(5):346-55. doi: 10.1002/acn3.299. eCollection 2016 May.

20.

How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?

Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K; PPMI Investigators.

Parkinsonism Relat Disord. 2016 Jul;28:62-7. doi: 10.1016/j.parkreldis.2016.04.027. Epub 2016 Apr 23.

PMID:
27132498

Supplemental Content

Loading ...
Support Center